Fas/fas ligand pathway, apoptosis, and clonal anergy involved in systemic acetylcholine receptor T cell epitope tolerance

Journal of Immunology

Volumn 166, Issue 5, 2001, Pages 3458-3467

  Deng, C ^a   Goluszko, E ^a   Christadoss, P ^a  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD69 ANTIGEN; CHOLINERGIC RECEPTOR; EPITOPE; FAS LIGAND; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; PEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CLONAL ANERGY; CONTROLLED STUDY; CYTOKINE PRODUCTION; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; LYMPHOCYTE PROLIFERATION; MOUSE; MYASTHENIA GRAVIS; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 0035284802     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.166.5.3458     Document Type: Article

References (57)

1. Genetic restriction of autoreactive acetylcholine receptor-specific T lymphocytes in myasthenia gravis
2. Immunotherapy for myasthenia gravis: A murine model
3. In vitro proliferative response and antibody titers specific to human acetylcholine receptor synthetic peptides in patients with myasthenia gravis and relation to HLA class II genes
4. Myasthenia gravis
5. Mutation at I-A β chain prevents experimental autoimmune myasthenia gravis
6. Major histocompatibility complex class II gene disruption prevents experimental autoimmune myasthenia gravis
7. + T cells are essential to induce experimental autoimmune myasthenia gravis
8. Long term corticosteroid treatment of myasthenia gravis
9. Immunosuppressive drugs: Azathioprine in the treatment of myasthenia gravis
10. Myasthenia gravis
11. A clinical therapeutic trial of cyclosporine in myasthenia gravis
12. Relapses in patients with myasthenia gravis treated with azathioprine
13. + cells sensitized to nicotinic acetylcholine receptor
14. Suppression of experimental autoimmune myasthenia gravis by epitope-specific neonatal tolerance to synthetic region α 146-162 of acetylcholine receptor
15. Determinant selection in murine experimental autoimmune myasthenia gravis: Effect of the bml2 mutation on T cell recognition of acetylcholine receptor epitopes
16. Autoimmune T cell recognition of human acetylcholine receptor: The sites of T cell recognition in myasthenia gravis on the extracellular part of the α subunit
17. Tolerance to a dominant T cell epitope in acetylcholine receptor molecule induces epitope spread and suppresses murine myasthenia gravis
18. Oral tolerance in experimental autoimmune encephalomyelitis. III. Evidence for clonal anergy
19. Amelioration of autoimmune encephalomyelitis by myelin basic protein synthetic peptide-induced anergy
20. Characterization of a tolerogenic T cell epitope of type II collagen and its relevance to collagen-induced arthritis
21. T cell deletion in high antigen dose therapy of autoimmune encephalomyelitis
22. Oral administration of an immunodominant human collagen peptide modulates collagen-induced arthritis
23. Antigen-driven peripheral immune tolerance: Suppression of experimental autoimmune encephalomyelitis and collagen-induced arthritis by aerosol administration of myelin basic protein or type II collagen
24. An altered peptide ligand mediates immune deviation and prevents autoimmune encephalomyelitis
25. Nasal administration of glutamate decarboxylase (GAD65) peptides induces Th2 responses and prevents murine insulin-dependent diabetes
26. Suppressor T cells generated by oral tolerization to myelin basic protein suppress both in vitro and in vivo immune responses by the release of TGF-β after antigen-specific triggering
27. + T cells
28. Oral tolerance in myelin basic protein T-cell receptor transgenic mice: Suppression of autoimmune encephalomyelitis and dose-dependent induction of regulatory cells
29. The Fas death factor
30. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome
31. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity
32. lpr and gld: Single gene models of systemic autoimmunity and lymphoproliferative disease
33. Experimental autoimmune myasthenia gravis in the mouse
34. Effect of MHC class I and CD8 cell deficiency on experimental autoimmune myasthenia gravis pathogenesis
35. Fas- and FasL-deficient mice are resistant to induction of autoimmune encephalomyelitis
36. CD95-induced apoptosis of lymphocytes in an immune privileged site induces immunological tolerance
37. Preferential use of a T cell receptor Vβ gene by acetylcholine receptor reactive T cells from myasthenia gravis-susceptible mice
38. In vivo preferential usage of TCR Vβ8 in Torpedo acetylcholine receptor immune response in the murine experimental model of myasthenia gravis
39. Experimental autoimmune myasthenia gravis in B10.BV8S2 transgenic mice: Preferential usage of TCRAV1 gene by lymphocytes responding to acetylcholine receptor
40. 2-microglobulin-deficient BALB/c mice
41. Stability of Th1 and Th2 population
42. Kinetics of mature T-cell development in the thymus
43. 10 thymocytes in vivo
44. T-cell apoptosis detected in situ during positive and negative selection in the thymus
45. Peripheral deletion of antigen-reactive T cells in oral tolerance
46. Intravenous injection of soluble antigen induces thymic and peripheral T-cell apoptosis
47. + T lymphocytes from MRL/lpr mice are resistant to receptor-mediated tolerance and apoptosis
48. Prevention of experimental myasthenia gravis by nasal administration of synthetic acetylcholine receptor T epitope sequences
49. Interferon γ (IFN-γ) is necessary for the genesis of acetylcholine receptor-induced clinical experimental autoimmune myasthenia gravis in mice
50. Mice with IFN-γ receptor deficiency are less susceptible to experimental autoimmune myasthenia gravis
51. The Th2 cytokine IL-4 is not required for the progression of antibody-dependent autoimmune myasthenia gravis
52. Suppression of experimental autoimmune myasthenia gravis in IL-10 gene-disrupted mice is associated with reduced B cells and serum cytotoxicity on mouse cell line expressing AChR
53. Direct evidence for anergy in T lymphocytes tolerized by oral administration of ovalbumin
54. Peripheral tolerance in T cell receptor-transgenic mice: Evidence for T cell anergy
55. Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement
56. CTLA-4 is required for the induction of high dose oral tolerance
57. Mechanisms of acquired thymic tolerance in vivo: Intrathymic injection of antigen induces apoptosis of thymocytes and peripheral T cell anergy